For (ex)entrepreneurs, families, wealthy individuals, business professionals, healthcare professionals and executives.
For family offices, foundations & charities and independent asset managers.
For institutional and wholesale clients.
For corporates, institutional investors and private equity.
Private Banking & Wealth Management
Professional Solutions
Investment Management
Van Lanschot Kempen closely monitors markets and economic developments. Stay informed and up to date on current topics. Read our articles, watch our videos and listen to our podcasts.
Private Banking
Investment management
Investment banking
Read more about our organisation, news, investor relations and our contribution to a sustainable society.
Read more about working at Van Lanschot Kempen and view current vacancies.
Read more about Evi, our online investment coach.
Read more about our expertise and offices in different countries.
Are you already a client or interested in our services? We are happy to help you.
We are happy to speak to you in person. Call us or click on the link below for more contact options and locations.
The Netherlands
0800 17 37
Belgium
+32 (0)32 86 69 80
Switzerland
+41 (0)43 377 11 11
We are happy to speak to you in person. Call us or click on the link below for more contact options and locations.
The Netherlands
+31 (0)20 348 87 00
United Kingdom
+44 (0)20 36 36 94 00
France
+33 (0)18 375 62 73
We are happy to speak to you in person. Call us or click on the link below for more contact options and locations.
The Netherlands
+31 (0)20 348 80 00
United Kingdom
+44 (0)20 36 36 94 00
United States of America
+1 (0)21 237 601 34
Nanobiotix
Nanobiotix is a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer
- Placement of 1,596,527 new shares, representing 10% of Nanobiotix’ pre-deal outstanding share capital
- Issue price of €15.75 per share represented a limited 1.4% discount versus the year-to-date average closing price
- Kempen & Co acted as Joint Global Coordinator and Joint Bookrunner in this transaction